featured
FDA Approves Voranigo for Grade 2 Astrocytoma or Oligodendroglioma
This is the first FDA-approved systemic therapy for patients with a susceptible IDH1 or IDH2 mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.